Developing a vaccine for broad protection against influenza A viruses
Official title: Engineering Protein Antigens and their Presentation from Multivalent Scaffolds
Funded at Georgia Institute of Technology · NIH-10884157 · Data updated 2026-11-12
This study is working on a new flu vaccine that aims to protect you from different types of flu viruses, including those that have caused pandemics in the past, by boosting your immune response in a stronger and longer-lasting way.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | July 7, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $816,638 |
| NIH project number | 5R01AI168408-02 |
| Project ID | NIH-10884157 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at risk of influenza infection, such as those with compromised immune systems, healthcare workers, and the elderly.
✕Less likely to help
Patients who are not at risk for influenza or those who have already been vaccinated with existing vaccines may not benefit from this research.
What this research studies
This research aims to create a vaccine that offers extensive protection against various strains of influenza A viruses, including those responsible for past pandemics. The approach focuses on eliciting a strong and lasting immune response by targeting a specific part of the virus called the stalk domain of hemagglutinin (HA). By using innovative techniques to shield the variable parts of the virus and enhance the immune response, the researchers hope to provide better protection against seasonal and pandemic influenza. This work is crucial as current vaccines often fail to protect against emerging strains due to their narrow focus.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that protects against multiple strains of influenza A, potentially reducing the impact of seasonal flu and preventing future pandemics.
How similar studies have gone: Previous research has shown promise in developing broadly neutralizing antibodies against influenza, indicating that this approach could be viable.
Where this research is happening
-
Georgia Institute of Technology
Atlanta, United States Active
Researchers
- Principal investigator: Kane, Ravi S. — Georgia Institute of Technology
- Study coordinator: Kane, Ravi S.
Related research
Other NIH-funded projects on the same topics.
-
Integrative AI tools to map protein sequences to structures and functions
A scientist team will develop advanced AI methods to better connect protein sequences, their 3D shapes, and how they work, using large biological data from sequencing and structures.
-
Robotic ultrasound-guided clot removal for stroke treatment
A new robot-assisted ultrasound system is being developed to help quickly reopen brain arteries during a stroke, with testing in patient-specific 3D-printed models and animal studies.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
Nanosensor blood test to spot early pancreatic cancer fingerprints
This project will use a nanosensor blood test to detect early-stage pancreatic cancer by reading a disease 'fingerprint' in patient serum.
-
Synergistic blood-brain barrier opening and targeted glioma treatment with pulsed electric fields
A new approach uses tiny, rapid electric pulses to safely disrupt the brain's protective barrier and enhance targeted treatment for malignant glioma.
-
Dexterous needle ablation for ventricular arrhythmia guided by MRI
A new MRI-guided, robot-assisted catheter delivers deeper heart tissue ablation to treat ventricular tachycardia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.